Drug guidance
Pembrolizumab for untreated locally advanced cervical cancer
5 October 2026
Condition
Cancer
-
Published on 05 Oct 2026
Last Updated on 05 Oct 2026
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Pembrolizumab 100 mg/4 mL solution for infusion, in combination with chemoradiotherapy, for untreated International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA locally advanced cervical cancer.
The decision was based on the acceptable clinical effectiveness and pricing proposal by the company.
Funding status
Pembrolizumab 100 mg/4 mL solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 December 2026.
Clinical indication, subsidy class and MediShield Life claims eligibility for pembrolizumab are provided in the Annex.